Tang Capital Management LLC grew its position in Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Rating) by 145.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,470,700 shares of the company’s stock after buying an additional 2,059,131 shares during […]
Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Rating) – Equities research analysts at William Blair issued their Q1 2024 earnings per share estimates for Pyxis Oncology in a note issued to investors on Thursday, May 11th. William Blair analyst A. Hsieh forecasts that the company will earn ($0.56) per share for the quarter. William Blair has […]
Pyxis Oncology (NASDAQ:PYXS – Get Rating) is one of 992 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Pyxis Oncology to similar businesses based on the strength of its analyst recommendations, dividends, earnings, valuation, risk, institutional ownership and profitability. Valuation & Earnings This table compares […]
Credit Suisse Group reissued their outperform rating on shares of Pyxis Oncology (NASDAQ:PYXS – Get Rating) in a research report released on Thursday morning, Benzinga reports. Credit Suisse Group currently has a $14.00 price target on the stock. Separately, Lifesci Capital reissued an outperform rating on shares of Pyxis Oncology in a research report on […]
Pyxis Oncology (NASDAQ:PYXS – Get Rating)‘s stock had its “outperform” rating restated by stock analysts at William Blair in a note issued to investors on Wednesday, PriceTargets.com reports. A number of other equities analysts have also weighed in on PYXS. Lifesci Capital reissued an “outperform” rating on shares of Pyxis Oncology in a research report […]